checkAd

     129  0 Kommentare First Surgeries Using Stryker’s Infinity With Adaptis and Everlast Successfully Completed in Europe

    Stryker (NYSE:SYK), a global leader in medical technologies, announced the successful completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology. The initial procedures were completed by Mr. David N. Townshend FRCS (Orth), Consultant Trauma & Orthopaedic Surgeon at North Tyneside General Hospital, United Kingdom, and are the start of the UK Infinity with Adaptis and Everlast study.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506564749/en/

    Anzeige 
    Handeln Sie Ihre Einschätzung zu Stryker Corp!
    Long
    305,47€
    Basispreis
    2,74
    Ask
    × 9,63
    Hebel
    Short
    368,05€
    Basispreis
    3,59
    Ask
    × 9,22
    Hebel
    Präsentiert von

    Den Basisprospekt sowie die Endgültigen Bedingungen und die Basisinformationsblätter erhalten Sie bei Klick auf das Disclaimer Dokument. Beachten Sie auch die weiteren Hinweise zu dieser Werbung.

    Stryker's Infinity with Adaptis and Everlast Total Ankle System, featuring Prophecy Surgical Planning, is designed to deliver efficient and accurate implementation. (Photo: Business Wire)

    Stryker's Infinity with Adaptis and Everlast Total Ankle System, featuring Prophecy Surgical Planning, is designed to deliver efficient and accurate implementation. (Photo: Business Wire)

    “We are delighted to have implanted the first patient using Stryker’s Infinity Total Ankle System with Adaptis and Everlast technology as part of the UK post-market clinical study,” said Mr. Townshend. “This new technology marks the next step of the Infinity Total Ankle System which has already shown promising outcomes and survivorship for our patients with end stage ankle arthritis. We look forward to sharing the results of this clinical study.”

    “Infinity with Adaptis builds on the legacy of the original Infinity Total Ankle, with a decade of clinical use. Recent publication data showed a 98.8% survivorship at two years of the original Infinity implant,1 demonstrating its safety and efficacy as a low-profile prosthesis for surgeons treating end-stage ankle arthritis,” said Markus Ochs, vice president and general manager of Stryker’s European Trauma & Extremities business. “These initial procedures highlight Stryker's dedication to innovation and commitment through research, enhancing our collaboration with surgeons.”

    The Infinity Total Ankle System consists of a titanium alloy tibial tray, cobalt chromium talar dome, and polyethylene insert and features a low-profile tibial implant design. The Adaptis 3D-printed total ankle implants2 incorporate porous metal components strategically designed to act as a scaffold, facilitating boney ingrowth.3* The Everlast highly cross-linked polyethylene inserts, blended with vitamin E, have been demonstrated to improve wear resistance.4 The interchangeability of the two talar options adds versatility to the system, designed for catering to diverse patient needs.

    Seite 1 von 2


    Diskutieren Sie über die enthaltenen Werte


    Business Wire (engl.)
    0 Follower
    Autor folgen

    First Surgeries Using Stryker’s Infinity With Adaptis and Everlast Successfully Completed in Europe Stryker (NYSE:SYK), a global leader in medical technologies, announced the successful completion of the first European surgeries using the Infinity Total Ankle System with Adaptis and Everlast technology. The initial procedures were completed by Mr. …